

Payal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4425512/publications.pdf>

Version: 2024-02-01

127
papers

6,186
citations

126858

33
h-index

79644

73
g-index

130
all docs

130
docs citations

130
times ranked

9596
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses. Archives of Pathology and Laboratory Medicine, 2022, 146, 154-165.	1.2	7
2	Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Modern Pathology, 2022, 35, 333-343.	2.9	34
3	The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. Clinical and Translational Medicine, 2022, 12, e695.	1.7	8
4	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
5	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. Clinical Genitourinary Cancer, 2021, 19, 12-21.e1.	0.9	22
6	SPARC is a key mediator of TGF β -induced renal cancer metastasis. Journal of Cellular Physiology, 2021, 236, 1926-1938.	2.0	29
7	Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging. European Radiology, 2021, 31, 314-324.	2.3	35
8	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. Journal of Urology, 2021, 205, 137-144.	0.2	28
9	Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor (GCT) management.. Journal of Clinical Oncology, 2021, 39, 387-387.	0.8	2
10	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	2.9	118
11	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	2.9	138
12	Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. Advances in Anatomic Pathology, 2021, 28, 251-257.	2.4	26
13	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. European Urology Open Science, 2021, 26, 83-87.	0.2	26
14	A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate. Case Reports in Pathology, 2021, 2021, 1-8.	0.2	4
15	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombusâ€”Safety Lead-in Results of a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1135-1142.	0.4	36
16	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. Clinical Cancer Research, 2021, 27, 4794-4806.	3.2	17
17	Determinants of renal cell carcinoma invasion and metastatic competence. Nature Communications, 2021, 12, 5760.	5.8	25
18	Basic Histopathologic Assessment of Germ Cell Tumors for Clinic and Research. Methods in Molecular Biology, 2021, 2195, 1-11.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	3.2	12
20	A renal cell carcinoma tumorgraft platform to advance precision medicine. <i>Cell Reports</i> , 2021, 37, 110055.	2.9	16
21	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	0.9	9
22	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	0.9	48
23	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 793-803.	3.2	117
24	Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. <i>EBioMedicine</i> , 2020, 51, 102526.	2.7	33
25	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	0.8	6
26	Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. <i>Nature Cell Biology</i> , 2020, 22, 1130-1142.	4.6	28
27	The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm. <i>Cancer Cell</i> , 2020, 38, 771-773.	7.7	23
28	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
29	Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 640-640.	0.8	3
30	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2020, 38, 416-416.	0.8	4
31	A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 647-647.	0.8	0
32	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2020, 38, 417-417.	0.8	1
33	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	5
34	IFN β -Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing. <i>Cancer Research</i> , 2019, 79, 1098-1112.	0.4	63
35	SCINA: Semi-Supervised Analysis of Single Cells in Silico. <i>Genes</i> , 2019, 10, 531.	1.0	150
36	Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. <i>Radiographics</i> , 2019, 39, 998-1016.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. <i>Nucleic Acids Research</i> , 2019, 47, 11623-11636.	6.5	30
38	Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase. <i>Oncogene</i> , 2019, 38, 5580-5598.	2.6	33
39	PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
40	Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 4542-4551.	3.2	19
41	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 478-484.	0.8	11
42	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	1.2	9
43	Radiomics in Kidney Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2019, 27, 1-13.	0.6	41
44	Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 633-633.	0.8	1
45	Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 645-645.	0.8	36
46	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 663-663.	0.8	0
47	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 651-651.	0.8	0
48	The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 632-632.	0.8	0
49	Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16096-e16096.	0.8	1
50	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16100-e16100.	0.8	0
51	Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4580-4580.	0.8	0
52	EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1079-1089.	1.9	13
53	Discriminative Spectral Pattern Analysis for Positive Margin Detection of Prostate Cancer Specimens using Light Reflectance Spectroscopy. <i>IJSE Transactions on Healthcare Systems Engineering</i> , 2018, 8, 144-154.	1.2	1
54	Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma. <i>European Radiology</i> , 2018, 28, 124-132.	2.3	8

#	ARTICLE	IF	CITATIONS
55	Development of a Patient-specific Tumor Mold Using Magnetic Resonance Imaging and 3-Dimensional Printing Technology for Targeted Tissue Procurement and Radiomics Analysis of Renal Masses. <i>Urology</i> , 2018, 112, 209-214.	0.5	32
56	Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1562-1570.	2.1	35
57	What is the role of nephrectomy following complete response to checkpoint inhibitors?. <i>Urology Case Reports</i> , 2018, 18, 60-63.	0.1	20
58	Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 485-488.	0.9	9
59	Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome" Not Quite "Burned Out". <i>Frontiers in Neurology</i> , 2018, 9, 20.	1.1	8
60	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	0.8	4
61	A patient-derived explant (PDX) model of hormone-dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	2.1	94
62	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. <i>Cell Metabolism</i> , 2018, 28, 793-800.e2.	7.2	193
63	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. <i>Cancer Discovery</i> , 2018, 8, 1142-1155.	7.7	138
64	Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer. <i>Oncotarget</i> , 2018, 9, 9415-9424.	0.8	4
65	Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e675-e680.	0.9	5
66	Low Testosterone Levels Result in Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue. <i>Urology</i> , 2017, 105, 175-180.	0.5	22
67	PBRM1 loss is a late event during the development of cholangiocarcinoma. <i>Histopathology</i> , 2017, 71, 375-382.	1.6	18
68	Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. <i>Cancer Discovery</i> , 2017, 7, 900-917.	7.7	128
69	Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory. <i>Clinical Chemistry</i> , 2017, 63, 1812-1820.	1.5	77
70	Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 2121-2130.	2.3	25
71	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , 2017, 17, 19.	0.6	26
72	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3706-3713.	0.8	34

#	ARTICLE	IF	CITATIONS
73	Improved imaging-pathology correlation with MR imaging-derived, 3D-printed, patient-specific whole-mount molds of the prostate.. Journal of Clinical Oncology, 2017, 35, 44-44.	0.8	1
74	Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative magnetic resonance imaging.. Journal of Clinical Oncology, 2017, 35, 460-460.	0.8	1
75	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer, 2016, 2, 91-99.	0.2	8
76	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Reports, 2016, 17, 2620-2631.	2.9	68
77	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15Åyear experience and lessons learned. BMC Urology, 2016, 16, 43.	0.6	24
78	The spectrum of renal cell carcinoma in adults. Abdominal Radiology, 2016, 41, 1052-1065.	1.0	5
79	Targeting renal cell carcinoma with a HIF-2 antagonist. Nature, 2016, 539, 112-117.	13.7	521
80	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of nonâ€“muscle-invasive high-grade bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 485.e7-485.e14.	0.8	19
81	Detecting positive surgical margins: utilisation of lightâ€“reflectance spectroscopy on <i>ex vivo</i> prostate specimens. BJU International, 2016, 118, 885-889.	1.3	8
82	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	0.5	16
83	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. Clinical Genitourinary Cancer, 2016, 14, e585-e594.	0.9	31
84	Light Reflectance Spectroscopy to Detect Positive Surgical Margins on Prostate Cancer Specimens. Journal of Urology, 2016, 195, 479-484.	0.2	13
85	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology, 2016, 29, 34-42.	2.9	55
86	Tumor Vascularity in Renal Masses: Correlation ofÂArterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. Clinical Genitourinary Cancer, 2016, 14, e25-e36.	0.9	44
87	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. World Journal of Urology, 2016, 34, 105-112.	1.2	7
88	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. Journal of Urology, 2016, 195, 180-187.	0.2	113
89	Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget, 2016, 7, 31508-31519.	0.8	22
90	Pretreatment biopsy analysis of DAB 2 IP identifies subpopulation of highâ€“risk prostate cancer patients with worse survival following radiation therapy. Cancer Medicine, 2015, 4, 1844-1852.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β -Catenin. Cell Reports, 2015, 13, 495-503.	2.9	57
92	Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma. Journal of Urology, 2015, 193, 451-456.	0.2	15
93	Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 111.e1-111.e7.	0.8	8
94	A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nature Communications, 2015, 6, 8699.	5.8	99
95	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e21-18.e26.	0.8	8
96	Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 23.e9-23.e14.	0.8	40
97	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nature Genetics, 2015, 47, 13-21.	9.4	310
98	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget, 2015, 6, 18038-18049.	0.8	23
99	High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget, 2015, 6, 16951-16962.	0.8	28
100	Prostate cancer detection using combined auto-fluorescence and light reflectance spectroscopy: ex vivo study of human prostates. Biomedical Optics Express, 2014, 5, 1512.	1.5	19
101	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. Journal of Urology, 2014, 191, 926-931.	0.2	29
102	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e23-30.e28.	0.8	24
103	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 191, 1671-1677.	0.2	22
104	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2014, 191, 28-34.	0.2	35
105	<i>Bap1</i> is essential for kidney function and cooperates with <i>Vhl</i> in renal tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16538-16543.	3.3	123
106	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 981-988.	0.8	39
107	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	0.5	18
108	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 54.e19-54.e26.	0.8	31

#	ARTICLE	IF	CITATIONS
109	DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 729-735.	0.4	6
110	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.2	69
111	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	13.5	257
112	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. <i>Lancet Oncology</i> , The, 2013, 14, 159-167.	5.1	383
113	Vulvar Fibroadenoma with Lactational Changes in Ectopic Breast Tissue. <i>Case Reports in Obstetrics and Gynecology</i> , 2013, 2013, 1-4.	0.2	8
114	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 137ra75.	5.8	159
115	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	9.4	791
116	Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 361-372.	0.2	2
117	Tailoring treatment of rectal adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2011, 22, 362-370.	0.7	6
118	Primary Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2011, 135, 822-830.	0.4	21
119	Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2011, 9, 1255-1265.	1.5	97
120	Immunohistochemical Expression of Neural Cell Adhesion Molecule in Wilms Tumors, Nephrogenic Rests, and Fetal and Postnatal Renal Cortices. <i>Pediatric and Developmental Pathology</i> , 2011, 14, 16-19.	0.5	6
121	Sclerosing lobular hyperplasia of breast: cytomorphologic and histomorphologic features: a case report. <i>CytoJournal</i> , 2006, 3, 8.	0.8	10
122	Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 201-204.	1.2	28
123	Fatty acid synthase expression in cutaneous melanocytic neoplasms. <i>Modern Pathology</i> , 2005, 18, 1107-1112.	2.9	46
124	Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. <i>Modern Pathology</i> , 2005, 18, 197-204.	2.9	113
125	Pathologic Quiz Case: Laryngeal Lesion in an Elderly Man. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 115-116.	1.2	2
126	Pathologic Quiz Case: Paratesticular Mass in a Young Man. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 589-590.	1.2	10

#	ARTICLE	IF	CITATIONS
127	Pathologic Quiz Case: Myxoid Tibial Lesion in a 31-Year-Old Man. Archives of Pathology and Laboratory Medicine, 2004, 128, e65-e66.	1.2	3